The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease

Study Assesses Immune Checkpoint Inhibitors Safety in Rheumatic Disease

May 18, 2018 • By Kurt Ullman

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Lightspring / shutterstock.com

Lightspring / shutterstock.com

Since they were first introduced in 2011, immune checkpoint inhibitors (ICIs) have become an important treatment for an expanding list of advanced cancers. Some concerns have been raised around the mechanism of action of these immunotherapy agents, making their use in rheumatic diseases (RD) problematical. An article in the March 2018 issue of Arthritis & Rheumatology takes an initial look at the risk of flare or other adverse effects in this population.1

You Might Also Like
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
Explore This Issue
May 2018
Also By This Author
  • ICD-10 Adoption Brings Major Changes to Practices

“ICIs work differently from chemotherapies that may deplete not only cancer cells, but also healthy ones,” says Uma Thanarajasingam, MD, PhD, an assistant professor of medicine within the Division of Rheumatology at the Mayo Clinic in Rochester, Minn. “ICIs target specific molecules that essentially act as brakes for the immune system, allowing the body to more efficiently attack the cancer cells.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

ICI Mechanism of Action Implicated in Autoimmune Disease

The problem arises because ICIs work in a nonspecific way. They inhibit the actions of CTLA-4, PD-1 and its ligands, which have been implicated in autoimmune diseases. Because of this, and the possibility of triggering flares or new disease activity in patients, people with RD were largely excluded from clinical trials. What happens when rheumatology patients receive ICIs remains unknown, thus physicians are hesitant to offer this effective immunotherapy to those with rheumatic diseases.

“I realized that a lot of our patients with RD at baseline were not included in the trials leading up to approval,” says Dr. Thanarajasingam. “Our patients also develop cancers, and we, of course, want them to be able to access potentially life-saving medications when possible.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Study Enters 16 Patients

Dr. Thanarajasingam and colleagues performed a retrospective study to identify all patients at the Mayo Clinic who had received ICI therapy between 2011 and 2016. They identified about 700 people and using specific diagnostic codes, those with preexisting rheumatic disease were identified.

Dr. Thanarajasingam

Dr. Thanarajasingam

Sixteen patients were entered into the review. Of these, 81% were female, with an average age of 68.3 years. The most common diseases were rheumatoid arthritis and polymyalgia rheumatica (five people each) followed by systemic lupus erythematosus and Sjögren’s syndrome (two people each).

Ten patients had previously been treated with a disease-modifying anti-rheumatic drug (DMARD) and two were still taking them at the time ICIs were initiated. Three more patients had already been prescribed glucocorticoids when the cancer treatment was started.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Rheumatoid Arthritis Tagged With: immune checkpoint inhibitor (ICI)Issue: May 2018

You Might Also Like:
  • The Immune Checkpoint Inhibitors Unleashed to Fight Cancer
  • Immune Checkpoint Inhibitors & Immune-Related Adverse Events
  • Immune-Related Adverse Events with Use of Checkpoint Inhibitors for Immunotherapy of Cancer
  • Complex Treatment: Cancer, Immunotherapy & Rheumatic Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.